These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22123671)

  • 1. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states.
    Farr S; Adeli K
    Curr Opin Lipidol; 2012 Feb; 23(1):56-61. PubMed ID: 22123671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-Like Peptide 2 (GLP-2) Stimulates Postprandial Chylomicron Production and Postabsorptive Release of Intestinal Triglyceride Storage Pools via Induction of Nitric Oxide Signaling in Male Hamsters and Mice.
    Hsieh J; Trajcevski KE; Farr SL; Baker CL; Lake EJ; Taher J; Iqbal J; Hussain MM; Adeli K
    Endocrinology; 2015 Oct; 156(10):3538-47. PubMed ID: 26132919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and emerging regulators of intestinal lipoprotein secretion.
    Xiao C; Dash S; Morgantini C; Lewis GF
    Atherosclerosis; 2014 Apr; 233(2):608-615. PubMed ID: 24534456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states.
    Farr S; Taher J; Adeli K
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(2):126-36. PubMed ID: 24801723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The physiologic role of incretin hormones: clinical applications.
    Cefalu WT
    J Am Osteopath Assoc; 2010 Mar; 110(3 Suppl 2):S8-S14. PubMed ID: 20382839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular protective properties of incretin-based therapies in type 2 diabetes.
    Simsek S; de Galan BE
    Curr Opin Lipidol; 2012 Dec; 23(6):540-7. PubMed ID: 23160401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S; Collier A; Elhadd T; Malik I
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis.
    Farr S; Baker C; Naples M; Taher J; Iqbal J; Hussain M; Adeli K
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1092-100. PubMed ID: 25675997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of incretin-based therapies in type 1 diabetes.
    Suen CS; Burn P
    Drug Discov Today; 2012 Jan; 17(1-2):89-95. PubMed ID: 21920456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.
    Hsieh J; Longuet C; Maida A; Bahrami J; Xu E; Baker CL; Brubaker PL; Drucker DJ; Adeli K
    Gastroenterology; 2009 Sep; 137(3):997-1005, 1005.e1-4. PubMed ID: 19482026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into incretin-based therapies for treatment of diabetic dyslipidemia.
    Stemmer K; Finan B; DiMarchi RD; Tschöp MH; Müller TD
    Adv Drug Deliv Rev; 2020; 159():34-53. PubMed ID: 32485206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
    Rizzo M; Rizvi AA; Spinas GA; Rini GB; Berneis K
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1495-503. PubMed ID: 19758106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal lipid absorption and transport in type 2 diabetes.
    Vergès B
    Diabetologia; 2022 Oct; 65(10):1587-1600. PubMed ID: 35908083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity.
    Hsieh J; Hayashi AA; Webb J; Adeli K
    Atheroscler Suppl; 2008 Sep; 9(2):7-13. PubMed ID: 18653387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of GLP-1 based therapies on diabetic dyslipidemia.
    Patel VJ; Joharapurkar AA; Shah GB; Jain MR
    Curr Diabetes Rev; 2014; 10(4):238-50. PubMed ID: 24998439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular actions of incretin-based therapies.
    Ussher JR; Drucker DJ
    Circ Res; 2014 May; 114(11):1788-803. PubMed ID: 24855202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin therapy for type 2 diabetes mellitus.
    Klonoff DC
    Adv Ther; 2010 Dec; 27(12):881-94. PubMed ID: 20978879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential cardiovascular effects of incretin-based therapies.
    Deacon CF; Marx N
    Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):337-51. PubMed ID: 22390806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.